UPDATE: Kura Oncology (KURA) Tops Q1 EPS by 1c; Expands Enrollment in Phase 2 Trial of Tipifarnib

Go back to UPDATE: Kura Oncology (KURA) Tops Q1 EPS by 1c; Expands Enrollment in Phase 2 Trial of Tipifarnib
(NASDAQ: KURA) Delayed: 9.62 +0.01 (0.10%)
Previous Close $9.61    52 Week High $8.90 
Open $9.73    52 Week Low $2.50 
Day High $9.84    P/E N/A 
Day Low $9.56    EPS $0.00 
Volume 864,958